To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea

Summary

The objective of this study is to investigate the safety and efficacy of (0.02 mg EE as betadex clathrate \[β-CDC\]) / 3 mg drospirenone (DRSP) for dysmenorrhea. In order to appropriately evaluate the efficacy of EE(β-CDC)/DRSP the study was set up as a placebo-controlled comparative study

Timeline

Start

2016-01

Primary completion

2017-09

Completion

2017-10

Drugs

Indications